IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

finance.yahoo.com · 2026-09-20

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure

TickrTrends take: IDEXX Laboratories' reaffirmation of long-term growth targets provides support for TickrTrends' undervalued designation, as the company's commitment to expanding its diagnostic pipeline suggests confidence in future revenue generation within the Healthcare sector. Investors focused on valuation metrics should monitor whether the company's pipeline developments translate into earnings growth that could justify current market pricing. The combination of diagnostic innovation and maintained growth guidance indicates potential for value creation as these initiatives mature.

Read the full story at finance.yahoo.com →